Solid tumors account for a substantial proportion of human cancers and include malignancies of organs such as the breast, lung, colon, liver, pancreas, stomach, and prostate.

Chemotherapy remains an important therapeutic approach for many of these cancers.

However, treatment failure frequently occurs because tumor cells are able to survive exposure to anticancer drugs.

Chemotherapy resistance can significantly reduce treatment effectiveness and contribute to disease recurrence and progression.

Resistance can be broadly classified as intrinsic or acquired.

Intrinsic resistance is present before treatment and reflects pre-existing biological characteristics of the tumor.

Acquired resistance develops after treatment as tumor cells adapt or evolve in response to therapeutic pressure.

Both forms of resistance are influenced by genetic, epigenetic, metabolic, and microenvironmental mechanisms.

A single tumor can contain multiple cellular populations with different levels of drug sensitivity.

This heterogeneity makes resistance particularly difficult to overcome.

Understanding the molecular basis of chemotherapy resistance is therefore essential for developing more effective treatment strategies.

Types of Chemotherapy Resistance

Chemotherapy resistance can develop through several overlapping mechanisms.

Increased Drug Efflux

One of the best-characterized mechanisms of multidrug resistance is increased drug efflux.

ATP-binding cassette transporters use cellular energy to export a wide range of compounds from cells.

P-glycoprotein, encoded by the ABCB1 gene, is a major example.

Other transporters include multidrug resistance-associated proteins and breast cancer resistance protein.

Overexpression of these transporters can reduce intracellular concentrations of chemotherapeutic drugs.

As a result, drug exposure may become insufficient to produce effective cytotoxicity.

Altered Drug Metabolism

Cancer cells can modify the metabolism of anticancer agents.

Increased activity of detoxification enzymes may convert active drugs into less toxic compounds.

Glutathione-related pathways can also contribute to drug detoxification.

This mechanism is particularly relevant for drugs that undergo intracellular oxidation or conjugation.

Altered metabolism can therefore reduce the effective concentration of chemotherapy within tumor cells.

Changes in Drug Targets

Chemotherapeutic agents generally act by interacting with specific cellular targets.

Mutations or modifications of these targets can reduce drug binding or alter drug sensitivity.

For example, alterations in enzymes involved in DNA replication or repair may affect the activity of drugs that target these processes.

Changes in target expression can also contribute to resistance.

Enhanced DNA Damage Repair

Many chemotherapeutic agents produce DNA damage.

Tumor cells can survive treatment if they efficiently repair this damage.

Several DNA repair pathways may contribute to resistance, including:

• Homologous recombination;
• Non-homologous end joining;
• Nucleotide excision repair;
• Base excision repair; and
• Mismatch repair.

Enhanced repair can reduce the accumulation of lethal DNA lesions.

Homologous Recombination

Homologous recombination repairs DNA double-strand breaks with high accuracy.

Increased activity of this pathway can protect cancer cells from drugs that generate DNA damage.

Conversely, tumors with defects in homologous recombination may show increased sensitivity to particular DNA-damaging treatments.

This biological relationship has contributed to the development of synthetic-lethal therapeutic strategies.

Defects in Apoptosis

Apoptosis is a major mechanism through which chemotherapy eliminates cancer cells.

Cancer cells can become resistant by suppressing apoptotic signaling.

Alterations involving the BCL-2 family of proteins, TP53, caspases, and mitochondrial signaling can reduce apoptosis.

Increased expression of anti-apoptotic proteins can allow tumor cells to survive despite substantial chemotherapy-induced damage.

TP53 and Chemotherapy Resistance

TP53 is a major regulator of cellular responses to DNA damage.

When severe DNA damage occurs, functional p53 can induce cell-cycle arrest, senescence, or apoptosis.

Loss or mutation of TP53 can disrupt these responses.

As a result, tumor cells may survive chemotherapy-induced damage.

However, the relationship between TP53 status and chemotherapy response varies between tumor types and individual treatment regimens.

Cell-Cycle Alterations

Many chemotherapeutic agents are most effective against actively dividing cells.

Tumor cells can reduce their proliferation rate or enter temporary quiescent states.

This can decrease their sensitivity to cell-cycle-dependent drugs.

Cell-cycle checkpoint alterations can also allow tumor cells to tolerate DNA damage.

Cancer Stem Cells

Cancer stem-like cells represent a population with self-renewal and tumor-initiating properties.

These cells may possess enhanced DNA repair, antioxidant defense, drug efflux, and survival signaling.

Such properties can allow them to survive chemotherapy.

After treatment, surviving cancer stem-like cells may contribute to tumor regeneration and relapse.

Epithelial-to-Mesenchymal Transition

Epithelial-to-mesenchymal transition is a cellular process involving loss of epithelial characteristics and acquisition of mesenchymal features.

EMT can increase cellular migration and invasion.

It has also been associated with chemotherapy resistance.

Transcription factors such as SNAIL, SLUG, TWIST, and ZEB family members can participate in EMT-associated changes.

EMT may also interact with cancer stem-cell properties and survival signaling.

Autophagy and Chemotherapy Resistance

Autophagy is a cellular recycling mechanism that removes damaged organelles and macromolecules.

Chemotherapy can induce autophagy in tumor cells.

In some contexts, autophagy protects cancer cells by providing nutrients and removing damaged cellular components.

This can allow tumor cells to survive therapeutic stress.

However, the relationship between autophagy and chemotherapy is context-dependent, and autophagy can also contribute to cell death under certain conditions.

Oxidative Stress and Redox Adaptation

Several chemotherapeutic agents increase oxidative stress.

Cancer cells can respond by activating antioxidant systems.

Glutathione, thioredoxin, superoxide dismutases, catalase, and NRF2-regulated pathways can help maintain redox homeostasis.

Enhanced antioxidant capacity may reduce oxidative damage caused by treatment.

Metabolic Reprogramming

Cancer cells frequently modify their metabolism to support growth and survival.

Metabolic reprogramming can also influence chemotherapy response.

Changes in glucose metabolism, mitochondrial activity, lipid metabolism, and amino-acid utilization can provide energy and reducing equivalents during treatment.

Altered metabolism may therefore support survival under therapeutic stress.

Tumor Microenvironment

Chemotherapy resistance is not determined exclusively by cancer-cell intrinsic mechanisms.

The tumor microenvironment contains fibroblasts, immune cells, endothelial cells, extracellular matrix, and signaling molecules.

These components can influence drug response.

Cancer-associated fibroblasts may release growth factors and cytokines that promote survival.

The extracellular matrix can also influence drug penetration and cellular signaling.

Hypoxia and Chemotherapy Resistance

Hypoxic regions are common in solid tumors because tumor growth can exceed the capacity of existing blood vessels.

Low oxygen levels activate hypoxia-inducible signaling pathways.

Hypoxia can alter metabolism, reduce proliferation, and increase survival signaling.

These changes can reduce the effectiveness of certain chemotherapeutic agents.

Cancer-Associated Fibroblasts

Cancer-associated fibroblasts can influence tumor growth and treatment resistance.

They may produce extracellular matrix proteins, cytokines, and growth factors.

These signals can activate survival pathways within cancer cells.

Interactions between cancer cells and fibroblasts may therefore contribute to persistent disease after treatment.

Inflammatory Signaling

Inflammatory cytokines can activate pathways involved in cancer-cell survival.

NF-κB, STAT3, and related signaling systems can promote resistance by increasing anti-apoptotic and stress-response proteins.

Chronic inflammation within the tumor microenvironment may therefore contribute to chemotherapy resistance.

Non-Coding RNAs

MicroRNAs and long non-coding RNAs can regulate genes involved in chemotherapy response.

MicroRNAs may influence apoptosis, drug transporters, DNA repair, and cell-cycle control.

Long non-coding RNAs can regulate chromatin structure, transcription, and signaling pathways.

Their dysregulation may contribute to both intrinsic and acquired resistance.

MicroRNAs and Resistance

Certain microRNAs can suppress tumor-suppressor genes or alter expression of drug-response proteins.

Changes in microRNA expression can influence apoptosis and DNA repair.

For example, increased expression of particular oncogenic microRNAs may suppress pathways required for chemotherapy-induced cell death.

Other microRNAs can enhance drug sensitivity by restoring expression of tumor-suppressive pathways.

Long Non-Coding RNAs

Long non-coding RNAs can contribute to resistance through multiple mechanisms.

They may act as molecular scaffolds, regulate chromatin-modifying proteins, influence transcription, or interact with microRNAs.

Altered lncRNA expression has been associated with resistance in breast, lung, colorectal, gastric, ovarian, and other solid tumors.

Epithelial-to-Mesenchymal Transition and Stemness

EMT and cancer stem-cell properties are closely interconnected.

Cells undergoing EMT may acquire stem-like characteristics.

These cells can demonstrate enhanced drug efflux, DNA repair, antioxidant defense, and resistance to apoptosis.

This combination can create a population capable of surviving chemotherapy and initiating recurrent tumors.

Figure 1. Major Molecular Mechanisms of Chemotherapy Resistance

                    CHEMOTHERAPY

                         │

          ┌──────────────┼──────────────┐

          ▼              ▼              ▼

      DNA DAMAGE     OXIDATIVE      CELLULAR

                       STRESS        STRESS

          │              │              │

          ▼              ▼              ▼

     DNA REPAIR      ANTIOXIDANT     AUTOPHAGY

      ↑ ↑ ↑           SYSTEMS           │

          │              │              │

          └───────┬──────┴──────┬──────┘

                  ▼             ▼

             CELL SURVIVAL   APOPTOSIS

                  │             │

                  ▼             X

          RESISTANT TUMOR CELLS

                  │

       ┌──────────┼───────────┐

       ▼          ▼           ▼

   DRUG EFFLUX   EMT     CANCER STEM CELLS

       │          │           │

       └──────────┴───────────┘

                  ▼

        TUMOR PERSISTENCE

                  │

                  ▼

             RECURRENCE

Figure 1: Schematic representation of major cellular and molecular mechanisms through which solid tumors can survive chemotherapy.

Review Design

The present article was prepared as a narrative review of molecular mechanisms associated with chemotherapy resistance in solid tumors.

Literature Search

Relevant scientific publications were considered from biomedical databases and peer-reviewed oncology and molecular biology journals.

Search terms included combinations of:

“chemotherapy resistance,” “solid tumors,” “multidrug resistance,” “ABC transporters,” “P-glycoprotein,” “DNA repair,” “apoptosis,” “autophagy,” “cancer stem cells,” “epithelial-to-mesenchymal transition,” “tumor microenvironment,” “hypoxia,” and “non-coding RNA.”

Inclusion Criteria

Studies were considered relevant when they investigated molecular or cellular mechanisms involved in resistance to chemotherapy in solid malignancies.

Particular attention was given to research involving:

• Drug transport and efflux;
• DNA damage and repair;
• Apoptotic signaling;
• Cancer stem cells;
• EMT;
• Autophagy;
• Metabolic adaptation;
• Tumor microenvironment; and
• Non-coding RNA regulation.

Exclusion Criteria

Studies unrelated to chemotherapy resistance or focused exclusively on hematological malignancies were not emphasized.

Data Synthesis

The available evidence was organized according to cancer-cell-intrinsic mechanisms, microenvironmental mechanisms, molecular signaling pathways, and therapeutic approaches.

Results

The reviewed evidence indicates that chemotherapy resistance is a multifactorial process.

Increased drug efflux through ABC transporters can reduce intracellular drug accumulation.

Alterations in drug metabolism and detoxification can further decrease effective drug concentrations.

Enhanced DNA repair allows tumor cells to recover from chemotherapy-induced DNA damage.

Defects in apoptosis enable cells to survive despite treatment-induced cellular injury.

Cancer stem-like cells, EMT, autophagy, metabolic adaptation, and antioxidant responses can provide additional mechanisms of survival.

The tumor microenvironment can further reinforce resistance through hypoxia, extracellular matrix interactions, cytokine signaling, and stromal-cell support.

Non-coding RNAs provide an additional regulatory layer by modifying expression of genes involved in drug transport, DNA repair, apoptosis, and cell survival.

These mechanisms can occur simultaneously within the same tumor, producing substantial therapeutic heterogeneity.

Chemotherapy resistance is one of the most significant challenges in the treatment of solid tumors.

The complexity of resistance reflects the biological heterogeneity of cancer.

Tumor cells can use multiple mechanisms simultaneously, and different cellular populations within the same tumor may depend on different resistance pathways.

Drug efflux represents a classical mechanism.

ABC transporters can decrease intracellular concentrations of multiple structurally unrelated drugs.

This multidrug-resistance phenotype can therefore affect several treatment regimens.

However, transporter expression alone does not explain all forms of resistance.

DNA repair is another major determinant.

Many chemotherapeutic agents act by producing DNA damage.

Cancer cells with enhanced repair capacity may survive treatment even when substantial DNA lesions occur.

Conversely, tumors carrying defects in specific DNA repair pathways can sometimes exhibit increased sensitivity to particular agents.

Apoptotic resistance is also central to treatment failure.

Even when chemotherapy successfully damages DNA, cancer cells must activate an appropriate cell-death response for treatment to be effective.

Alterations in TP53, BCL-2 family proteins, mitochondrial signaling, and caspase activation can interfere with this process.

Cancer stem-like cells provide another important explanation for tumor persistence.

These cells may be relatively resistant to conventional treatment and can regenerate tumor populations after therapy.

Their enhanced DNA repair and antioxidant capacity may contribute to this phenotype.

The tumor microenvironment adds another layer of complexity.

Hypoxia can reduce proliferation and modify cellular metabolism.

Cancer-associated fibroblasts and other stromal cells can provide survival signals.

The extracellular matrix can alter drug penetration and activate integrin-mediated signaling.

Consequently, successful treatment may require targeting both malignant cells and their supportive microenvironment.

Therapeutic Strategies to Overcome Chemotherapy Resistance

Several approaches are being investigated to overcome resistance.

Targeting DNA Repair

DNA repair pathways represent attractive therapeutic targets.

Inhibiting repair mechanisms can increase the accumulation of chemotherapy-induced DNA damage.

PARP inhibition provides an important example of exploiting DNA repair vulnerabilities.

Tumors with defects in homologous recombination may be particularly sensitive to PARP inhibition.

This concept illustrates how molecular profiling can guide treatment selection.

Targeting Drug Efflux

Inhibition of ABC transporters has been explored as a strategy for overcoming multidrug resistance.

The objective is to increase intracellular concentrations of chemotherapy.

However, clinical translation has been challenging because transporters also perform physiological functions in normal tissues.

The development of selective inhibitors with acceptable safety profiles remains an important research objective.

Targeting Cancer Stem Cells

Cancer stem-cell populations may represent an important reservoir of therapy-resistant cells.

Strategies targeting stemness-associated pathways could potentially reduce tumor regeneration.

However, cancer stem-cell biology varies among tumor types, and effective selective targeting remains challenging.

Nanotechnology-Based Approaches

Nanoparticle-based drug delivery systems may improve chemotherapy distribution and intracellular drug delivery.

Nanocarriers can potentially protect drugs from premature degradation and improve accumulation within tumors.

Some approaches are being developed to co-deliver chemotherapy with molecular inhibitors targeting resistance pathways.

Personalized Medicine

The molecular heterogeneity of solid tumors supports the use of personalized treatment strategies.

Genomic profiling can identify mutations and pathways that influence drug response.

Transcriptomic and epigenetic information may provide additional predictive value.

Combining molecular data with clinical characteristics could allow treatment selection based on the specific resistance mechanisms present within an individual tumor.

Future Perspectives

Future research should move beyond identifying individual resistance mechanisms toward understanding interactions between multiple pathways.

Single-cell sequencing may help identify resistant cellular populations within heterogeneous tumors.

Spatial molecular technologies may clarify how tumor cells interact with stromal and immune components.

Artificial intelligence may help integrate genomic, transcriptomic, proteomic, and clinical data to predict treatment response.

Another promising direction is adaptive treatment, in which therapy is modified according to changes in tumor molecular characteristics during treatment.

Liquid biopsy approaches may facilitate repeated assessment of tumor evolution without requiring repeated tissue biopsies

Chemotherapy resistance in solid tumors is a complex and dynamic process involving multiple molecular and cellular mechanisms.

Drug efflux, altered drug metabolism, enhanced DNA repair, impaired apoptosis, cell-cycle adaptation, autophagy, metabolic reprogramming, oxidative stress responses, cancer stem cells, EMT, and tumor microenvironmental signaling can all contribute to treatment failure.

These mechanisms frequently interact, allowing tumor cells to compensate when one survival pathway is inhibited.

Consequently, approaches targeting multiple resistance mechanisms may be more effective than strategies directed against a single pathway.

Molecular profiling can help identify resistance-associated alterations and guide personalized treatment.

Future integration of targeted therapies, DNA repair inhibitors, redox modulation, nanotechnology, immunotherapy, and microenvironment-directed strategies may provide new opportunities to overcome chemotherapy resistance and improve outcomes for patients with solid tumors.

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. Journal of Pathology. 2005;205:275–292.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer. 2002;2:48–58.
3. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer. 2018;18:452–464.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer. 2013;13:714–726.
5. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309.
6. Zahreddine H, Borden KLB. Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology. 2013;4:28.
7. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–1158.
8. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clinical Cancer Research. 2014;20:540–547.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
10. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12:31–46.
11. Batlle E, Clevers H. Cancer stem cells revisited. Nature Medicine. 2017;23:1124–1134.
12. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology. 2017;14:611–629.
13. Nieto MA, Huang RYJ, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166:21–45.
14. Chen W, Bottger CA, Saadatzadeh MR, et al. Autophagy and chemotherapy resistance in cancer. Cancer Letters. 2021;519:1–13.
15. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discovery. 2019;9:1167–1181.
16. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 2013;19:1423–1437.
17. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews Cancer. 2009;9:665–674.
18. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer. 2013;13:714–726.
19. Gottesman MM. Mechanisms of cancer drug resistance. Annual Review of Medicine. 2002;53:615–627.
20. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564.